Skip Nav Destination
Close Modal
Update search
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Article Type
Date
Availability
1-7 of 7
Keywords: cardiotoxicity
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Articles
Journal:
Clinical Science
Clin Sci (Lond) (2024) 138 (6): 413–434.
Published: 20 March 2024
...Yiming Bo; Xin Zhao; Liliang Li Drug-induced cardiotoxicity has become one of the most common and detrimental health concerns, which causes significant loss to public health and drug resources. Cannabinoid receptors (CBRs) have recently achieved great attention for their vital roles...
Articles
Chayodom Maneechote, Thawatchai Khuanjing, Benjamin Ongnok, Apiwan Arinno, Nanthip Prathumsap, Titikorn Chunchai, Busarin Arunsak, Wichwara Nawara, Siriporn C. Chattipakorn, Nipon Chattipakorn
Journal:
Clinical Science
Clin Sci (Lond) (2022) 136 (11): 841–860.
Published: 01 June 2022
... to cardiotoxicity following a high cumulative dose of doxorubicin (DOX). A mitochondrial division inhibitor-1 (Mdivi-1) and fusion promoter (M1) have been shown to be cardioprotective in a variety of cardiovascular settings, however, their anticardiotoxic efficacy against DOX therapy remains unclear. We therefore...
Articles
In Collection
Cardiovascular-Oncology
Zuzana Pokorná, Petra Kollárová-Brázdová, Olga Lenčová-Popelová, Eduard Jirkovský, Jan Kubeš, Yvona Mazurová, Michaela Adamcová, Magdalena Holečková, Vladimír Palička, Tomáš Šimůnek, Martin Štěrba
Journal:
Clinical Science
Clin Sci (Lond) (2022) 136 (1): 139–161.
Published: 07 January 2022
... on chronic ANT cardiotoxicity in a rabbit model previously validated with the cardioprotective agent dexrazoxane (DEX) with focus on post-treatment follow-up (FU). Chronic cardiotoxicity was induced by daunorubicin (DAU; 3 mg/kg/week for 10 weeks). Perindopril (0.05 mg/kg/day) was administered before...
Includes: Supplementary data
Articles
In Collection
Cardiovascular-Oncology
Journal:
Clinical Science
Clin Sci (Lond) (2021) 135 (10): 1311–1332.
Published: 28 May 2021
... ) 05 01 2021 07 05 2021 11 05 2021 © 2021 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society 2021 anthracycline cardiomyopathy cardiotoxicity reactive oxygen species topoisomerases Anthracyclines are highly effective...
Includes: Supplementary data
Articles
In Collection
Cardiovascular-Oncology
Journal:
Clinical Science
Clin Sci (Lond) (2020) 134 (19): 2595–2622.
Published: 14 October 2020
... clinical implications of treating patients with these drugs, such as increased arrhythmia burden, biventricular cardiac dysfunction, and impaired recovery from cardiotoxicity. Recommendations for future directions for preclinical and clinical work are made, highlighting the possible role of PI3Kα...
Articles
Journal:
Clinical Science
Clin Sci (Lond) (2020) 134 (13): 1859–1885.
Published: 17 July 2020
...Keith Dadson; Oscar Calvillo-Argüelles; Paaladinesh Thavendiranathan; Filio Billia Despite the known risk of cardiotoxicity, anthracyclines are widely prescribed chemotherapeutic agents. They are broadly characterized as being a robust effector of cellular apoptosis in rapidly proliferating cells...
Articles
Zuzana Pokorna, Eduard Jirkovsky, Marketa Hlavackova, Hana Jansova, Anna Jirkovska, Olga Lencova-Popelova, Petra Brazdova, Jan Kubes, Dita Sotakova-Kasparova, Yvona Mazurova, Michaela Adamcova, Lucie Vostatkova, Kristyna Holzerova, Frantisek Kolar, Tomas Simunek, Martin Sterba
Journal:
Clinical Science
Clin Sci (Lond) (2019) 133 (16): 1827–1844.
Published: 27 August 2019
... inhibitors (PIs) are modern targeted anticancer drugs, they have been associated with a certain risk of cardiotoxicity and heart failure (HF). Recently, PIs have been combined with anthracyclines (ANTs) to further boost their anticancer efficacy. However, this raised concerns regarding cardiac safety, which...
Includes: Supplementary data